Everolimus Prolongs Progression-Free Survival Biomed Middle East By jamal, on December 1st, 2011 The treatment combination of everolimus and octreotide long-acting repeatable (LAR), a somatostatin analogue that has shown antitumor activity, led to a clinically meaningful five-month delay in tumour growth, ... |
